Transplant News and Research

RSS

Statins may help protect stem cell transplant patients from GVHD

Cholesterol-lowering drugs known as statins are among the most prescribed medicines in the U.S. Now a new study by researchers at Fred Hutchinson Cancer Research Center indicates that statins may protect stem cell transplant patients from one of the most serious complications of the life-saving cancer therapy: graft-versus-host disease, or GVHD. The findings are reported in the Nov. 4 first edition of the journal Blood.

5 Dec 2009

Amber Pharmacy receives ACHC accreditation

Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services.

4 Dec 2009

Orthofix International announces the launch of its FUSION Lateral OA Brace

Orthofix International announced today that its sports medicine division, BREG, has expanded its successful line of FUSION® functional knee braces by introducing the FUSION® Lateral OA Brace, which features an ultra-thin low-profile hinge designed for individuals suffering from lateral compartment osteoarthritis (OA).

4 Dec 2009

Bells on Bay St. inspires business leaders to register their consent for organ and tissue donation

Three hundred business leaders took time from the hustle and bustle of attending holiday gatherings and trying to find the perfect gift for loved ones, to reflect this morning upon the urgent need to make one other vital gift - registration of consent to be an organ and tissue donor.

4 Dec 2009

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009

Research study shows usage of stem cell-based therapies for treating age-related macular degeneration

An international team of scientists has rescued visual function in laboratory rats with eye disease by using cells similar to stem cells. The research shows the potential for stem cell-based therapies to treat age-related macular degeneration in humans.

4 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.

4 Dec 2009

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Surgeons and other healthcare professionals specialising in solid organ transplants have been issued with expert advice to guide them through the complex clinical issues posed by the global H1N1 (swine flu) pandemic.

4 Dec 2009

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Allos Therapeutics, Inc. today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes.

3 Dec 2009

Enrollment closed early in Cubist Pharmaceuticals' ecallantide Phase 2 program

Cubist Pharmaceuticals, Inc. today announced the early closing of enrollment in its ecallantide Phase 2 program. Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery, is now known as CB-500,929. After a regularly scheduled review meeting, the Data Safety Monitoring Board (DSMB) contacted the company to recommend a temporary suspension in enrollment in one of the CB-500,929 trials, CONSERV-2.

3 Dec 2009

Brandeis University researchers appraises economic benefits of BOS-P lens

Today, in the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper appraising the economic benefits of the BOS-P, a highly precise scleral lens used to treat severe cornea or ocular surface disease. A companion paper on the clinical benefits has been published online and will appear in the journal's January issue.

3 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Ege University’s surgical team completes first phase of certification training on ‘Syncardia Total Artificial Heart’

On Nov. 30 and Dec. 1, the surgical team from Ege University in Izmir, Turkey, led by Prof. Mustafa Ozbaran, head of the Transplant and Assist Device Program, completed the first phase of certification training for the SynCardia temporary CardioWest™ Total Artificial Heart in Paris.

2 Dec 2009

Genzyme ships vials of newly produced Cerezyme

Genzyme Corporation announced today that it has begun shipping vials of newly produced Cerezyme® (imiglucerase for injection) manufactured at its Allston Landing plant.

2 Dec 2009

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

StemCyte, Inc. concluded an exclusive license and commercialization agreement with Academia Sinica, the National Laboratory of Taiwan, for certain proprietary methods and Intellectual Property (IP) related to the treatment of Chronic Stroke with stem cells.

1 Dec 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Study provides first direct evidence of cigarette smoke's role in cardiac allograft rejection

A study conducted at the University of Maryland School of Medicine in Baltimore provides the first direct evidence that cigarette smoke exposure prior to a heart transplant in either the donor, recipient, or both, accelerates the death of a transplanted heart.

25 Nov 2009

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups

25 Nov 2009

Transplant News and Research

Statins may help protect stem cell transplant patients from GVHD

Amber Pharmacy receives ACHC accreditation

Orthofix International announces the launch of its FUSION Lateral OA Brace

Bells on Bay St. inspires business leaders to register their consent for organ and tissue donation

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

Research study shows usage of stem cell-based therapies for treating age-related macular degeneration

New SPC3649 drug found effective in treating HCV infections

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Enrollment closed early in Cubist Pharmaceuticals' ecallantide Phase 2 program

Brandeis University researchers appraises economic benefits of BOS-P lens

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Ege University’s surgical team completes first phase of certification training on ‘Syncardia Total Artificial Heart’

Genzyme ships vials of newly produced Cerezyme

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

Kiadis Pharma commences enrollment in multinational ATIR study

Gentium announces financial results for the third quarter ended September 30, 2009

Study provides first direct evidence of cigarette smoke's role in cardiac allograft rejection

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News